The Vall d´Hebron Institute of Oncology (VHIO)
Established in 2006, VHIO is a leading comprehensive cancer center of excellence where its researchers and physician-scientists adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer.
Undertaking one of Spain´s most dynamic cancer research programs and recognized as a leading reference in drug discovery from concept to the clinic (phase I-II clinical trials), VHIO is dedicated to delivering on the promise of ´precision´medicine in oncology – turning cancer discovery into more effective treatments and better practice for the care of patients.
ICREA is a foundation supported by the Catalan Government established to strengthen the research system in Catalunya, recruiting and retaining top researchers in the Catalan R&D system. They have an excellent track record in technology transfer and lab-to-market initiatives in general.
HealthEquity is a Spanish venture capital firm investing in early-stage companies in the healthcare sector, with a special focus on biotechnology and medical devices. Founded by the Barcelona Medical Association and the financial group Riva y Garcia, HealthEquity is looking for projects to bring successful innovative life science companies to the marketplace and to foster the Catalan and Spanish biotech ecosystem.
Alta Life Sciences
Alta Life Sciences is a new leading venture capital investment firm headquartered in Barcelona, that acts as investment advisor to the fund ALSS I FCR. The fund invests in companies at all stages of development: from seed financing through commercial growth, and in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.
AurorA Science is a biotech investment company integrating an innovative financial and industrial approach in the research and development challenge. The company is focused on independent and entrepreneurial biotech start-ups in Europe with high therapeutic potential, providing industrial and financial support.
This company is capitalized by Innvierte, an investment program of CDTI, E.P.E.